Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2014 | 1 |
2022 | 1 |
2024 | 1 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis.
Thromb Res. 2014 Dec;134(6):1214-9. doi: 10.1016/j.thromres.2014.09.039. Epub 2014 Oct 8.
Thromb Res. 2014.
PMID: 25457583
Review.
BACKGROUND: Current clinical practice guidelines all recommend the use of therapeutic doses of low molecular weight heparins (LMWH) for the initial and long-term treatment of cancer-related thrombosis. The use of vitamin-K antagonists (VKA) is acceptable if LMWH is not ava …
BACKGROUND: Current clinical practice guidelines all recommend the use of therapeutic doses of low molecular weight heparins (LMWH) for the …
Case-fatality rate of major bleeding events in patients on dual antiplatelet therapy after percutaneous coronary intervention: A systematic review and meta-analysis.
Tritschler T, Patel A, Kraaijpoel N, Bhatt DL, De Luca G, Di Santo P, Feres F, Costa RA, Hibbert B, Isshiki T, Le Gal G, Castellucci LA.
Tritschler T, et al. Among authors: castellucci la.
Res Pract Thromb Haemost. 2022 Nov 4;6(7):e12834. doi: 10.1002/rth2.12834. eCollection 2022 Oct.
Res Pract Thromb Haemost. 2022.
PMID: 36349260
Free PMC article.
The CFR of major bleeding was 10.8% (95% confidence interval [CI], 7.1-16.2; I (2) = 50%) in the entire study population, and 13.8% (95% CI, 6.5-27.1; I (2) = 28%), 11.2% (95% CI, 6.7-18.0; I (2) = 0%), and 5.8% (95% CI, 3.0-11.1; I (2) = 0%) in those on short-term (6 mont …
The CFR of major bleeding was 10.8% (95% confidence interval [CI], 7.1-16.2; I (2) = 50%) in the entire study population, and 13.8% (95% CI, …
Item in Clipboard
Thrombocytopenia with and without thrombosis following COVID-19 vaccination: long-term management.
Ge M, Ladha D, Lymer J, Pancic S, Carrier M, Le Gal G, Castellucci LA.
Ge M, et al. Among authors: castellucci la.
Res Pract Thromb Haemost. 2024 Mar 1;8(2):102357. doi: 10.1016/j.rpth.2024.102357. eCollection 2024 Feb.
Res Pract Thromb Haemost. 2024.
PMID: 38550529
Free PMC article.
BACKGROUND: Since administration of COVID-19 vaccines, there has been growing evidence of thrombotic and thrombocytopenic events following vaccination. However, there remains limited data on long-term management of these adverse hematologic events. KEY CLINICAL QUESTION: W …
BACKGROUND: Since administration of COVID-19 vaccines, there has been growing evidence of thrombotic and thrombocytopenic events following v …
Item in Clipboard
Cite
Cite